| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
- JNJ-632
-
- $64.00
-
2026-04-22
- CAS:1572510-42-9
- Purity: 99.17%
- Supply Ability: 10g
|
| | JNJ-632 Basic information |
| Product Name: | JNJ-632 | | Synonyms: | JNJ-632;JNJ-632; JNJ 632; JNJ632;CS-2776;N-(4-fluoro-3-methyl-phenyl)-3-[[(3S)-tetrahydrofuran-3-yl]sulfamoyl]benzamide;N-(4-fluoro-3-methylphenyl)-3-[[(3S)-oxolan-3-yl]sulfamoyl]benzamide;Benzamide, N-(4-fluoro-3-methylphenyl)-3-[[[(3S)-tetrahydro-3-furanyl]amino]sulfonyl]-;N-(4-Fluoro-3-methylphenyl)-3-[[[(3S)-tetrahydro-3-furanyl]amino]sulfonyl]benzamide;(S)-N-(4-Fluoro-3-methylphenyl)-3-(N-(tetrahydrofuran-3-yl)sulfamoyl)benzamide | | CAS: | 1572510-42-9 | | MF: | C18H19FN2O4S | | MW: | 378.42 | | EINECS: | | | Product Categories: | API | | Mol File: | 1572510-42-9.mol |  |
| | JNJ-632 Chemical Properties |
| density | 1.39±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Ethanol:76.0(Max Conc. mg/mL);200.84(Max Conc. mM) | | form | A crystalline solid | | pka | 10.37±0.20(Predicted) | | color | White to off-white |
| | JNJ-632 Usage And Synthesis |
| Uses | JNJ-632 is a hepatitis B virus (HBV) capsid assembly modulator (CAM). | | in vivo | The single dose PK profile of JNJ-632 is evaluated in C57BL/6 mice following intravenous (iv) and oral (po) administration. JNJ-632 has a moderate plasma clearance of 34 mL/min/kg and a moderate volume of distribution of 1.3 L/kg. The oral bioavailability is 40% following oral administration of 10 mg/kg and 66% following oral administration of 50 mg/kg. JNJ-632 has moderate terminal elimination half-life with t1/2s of 0.42±0.06 h, 1.1±0.67 h, 2.4±2.3 h, and 5.3±0.1 h for 2.5 mg/kg (iv), 10 mg/kg (po), 50 mg/kg (po), and 50 mg/kg (sc).To circumvent the first pass metabolism, JNJ-632 is also dosed subcutaneously at 50 mg/kg in C57BL/6 mice and this results in a concentration in plasma after 24 h of dosing of 102 ng/mL and concentration in liver after 24 h of dosing of 1297 ng/g[1]. | | References | [1] Vandyck K, et al. Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV). J Med Chem. 2018 Jul 26;61(14):6247-6260. DOI:10.1021/acs.jmedchem.8b00654 |
| | JNJ-632 Preparation Products And Raw materials |
|